\n \n \n “. concat(self. i18n. t(‘search. voice. recognition_retry’), “\n
Supply agreement after a new tender won with a foreign organization that operates basically in Latin America
Product acquisition planned for the fourth quarter of 2022 and the first part of 2023
REHOVOT, Israel and HOBOKEN, N. J. , July 6, 2022 (GLOBE NEWSWIRE) — Kamada Ltd. (NASDAQ)
“We are incredibly pleased with this origin agreement, which strongly validates our ability to increase sales of our newly acquired portfolio of 4 fda-approved plasma-derived special IgGs in overseas markets,” said Amir London, KAMADA’s chief executive officer. The order, which is based on obtaining a new tender, is indicative of the prospect of significant advertising of those products in overseas markets beyond the United States and Canada, and we intend to continue to pursue more advertising contracts in key strategic territories. “
VARIZIG [Varicella Zoster Immune Globulin (Human)], one of the 4 FDA-approved advertising products recently acquired through Kamada, expresses antibodies against the varicella-zoster virus and is indicated for post-exposure prophylaxis of chickenpox in patients of maximum threat. Patient groups, adding immunocompromised children, newborns and pregnant women. VARIZIG is intended to decrease the severity of chickenpox infections in these patients. The U. S. Centers for Disease Control (CDC)threat of serious disease lacking evidence of immunity to chickenpox. The product is the only IGG product approved by the FDA for this indication.
VARIZIG is manufactured through Emergent BioSolutions (NYSE: EBS) at its Winnipeg, MB, Canada plant, a Development and Manufacturing Services Agreement (CDMO).
About Kamada Kamada Ltd. (the “Company”) is a vertically incorporated global biopharmaceutical company focused on specialty plasma-derived therapeutics, with a diverse portfolio of marketed products, a physically powerful pipeline and manufacturing capabilities. The Company’s strategy is aimed at the successful expansion of our existing business activities, as well as our production experience and progression in the plasma-derived biopharmaceutical market. The company’s portfolio of advertised products includes its FDA-developed and approved GLASSIA® and KEDRAB® products, as well as its recently FDA-approved plasma-derived hyperimmune products CYTOGAM®, HEPAGAM B®, VARIZIG® and WINRHO®SDF. The Company has 4 other plasma-derived products that are registered in markets outside of the United States. The Company distributes its portfolio of advertising products directly and through strategic partners or third-party providers in more than 30 countries, in addition to the United States, Canada, Israel and Russia. Array Brazil, Argentina, India and other countries in Latin America and Asia. The Company has a diverse portfolio of products in progress, adding an inhaled AAT for the remedy of AAT deficiency for which the Company is currently conducting the InnovAATe clinical trial, a pivotal Phase 3 randomized, double-blind, placebo-controlled trial. . The company leverages its experience and presence in the Israeli pharmaceutical market to distribute more than 20 third-party manufactured products in Israel and recently added 11 biosimilar products to its Israeli distribution portfolio, which, subject to approvals from the EMA and the Ministry of Health of Israel, is expected to launch in Israel between 2022 and 2028. FIMI Opportunity Fund, the leading personal equity investor in Israel, is the Company’s largest shareholder, holding approximately 21% of the Notable and Not Unusual Shares.
Caution Regarding Forward-Looking Statements This release includes forward-looking statements within the meaning of Section 21E of the United States Securities Exchange Act of 1934, as amended, and the safe harbor provisions of the Securities Litigation Reform Act. United States Private 1995Arraythe statements are statements that are not old facts, adding statements relating to: 1) the source of the $11. 4 million proceeds is expected to occur from the fourth quarter of 2022 through the first part of 2023, 2) positive statements regarding Kamada’s ability to build sales of our recently acquired portfolio of 4 FDA-approved plasma-derived specialty IgGs in foreign markets, and 3) statements regarding significant prospective advertising of those products in foreign markets beyond the United States and Canada, and Kamada’s goal of continuing with the studios its other advertising contracts in key strategic territories. Forward-looking statements are based on Kamada’s existing wisdom and existing ideals and expectations regarding imaginable long-term events and are subject to risks, uncertainties and assumptions. The actual effects and timing of events may differ materially from those expected in those forward-looking statements due to various factors, including, but not limited to, the continued evolution of the COVID-19 pandemic, its scope, effects and duration. , supply chain disruptions due to the COVID-19 pandemic, Kamada’s ability to effectively integrate the new product portfolio into its existing product portfolio, regulatory delays, market conditions, prevailing market and the economic, industrial effect or general politician. situations in the United States, Israel or elsewhere, and other dangers detailed in Kamada’s filings with the United States Securities and Exchange Commission (the “SEC”), adding those discussed in its most recent Annual Report at Form 20-F and in all forthcoming reports on Form 6-K, each of which is filed either through the SEC and can be found on the SEC’s website at www. sec. gov. Forward-looking statements made in this document speak only as of the date of this announcement and Kamada assumes no legal responsibility to publicly update such forward-looking statements to reflect future events or circumstances, unless otherwise required by law.
CONTACTS :Chaime OrlevDirector financierIR@kamada. com
Bob YedidLifeSci Advisors, LLC646-597-6989Bob@LifeSciAdvisors. com